A route-based pathway analysis framework integrating mutation information and gene expression data.

We propose a new way of analyzing biological pathways in which the analysis combines both transcriptome data and mutation information and uses the outcome to identify "routes" of aberrant pathways potentially responsible for the etiology of disease. Each pathway route is encoded as a Bayesian Network which is initialized with a sequence of conditional probabilities which are designed to encode directionality of regulatory relationships encoded in the pathways, i.e. activation and inhibition relationships. First, we demonstrate the effectiveness of our model through simulation in which the model was able to easily separate Test samples from Control samples using fictitiously perturbed pathway routes. Second, we apply our model to analyze the Breast Cancer data set, available from TCGA, against many cancer pathways available from KEGG and rank the significance of identified pathways. The outcome is consistent with what have already been reported in the literature. Third, survival analysis has been carried out on the same data set by using pathway routes as features. Overall, we envision that our model of using pathway routes for analysis can further refine the conventional ways of subtyping cancer patients as it can discover additional characteristics specific to individual's tumor.

[1]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[2]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[3]  Francesco C Stingo,et al.  INCORPORATING BIOLOGICAL INFORMATION INTO LINEAR MODELS: A BAYESIAN APPROACH TO THE SELECTION OF PATHWAYS AND GENES. , 2011, The annals of applied statistics.

[4]  R. Kidd,et al.  Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. , 2013, Breast cancer.

[5]  Søren Højsgaard,et al.  Graphical Independence Networks with the gRain Package for R , 2012 .

[6]  J. Massagué TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[7]  Trevor Hastie,et al.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.

[8]  J. Gomez-Cambronero Phosphatidic acid, phospholipase D and tumorigenesis☆ , 2013, Advances in biological regulation.

[9]  G. Semenza,et al.  Hypoxia-inducible factor 1 and breast cancer metastasis , 2015, Journal of Zhejiang University-SCIENCE B.

[10]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[11]  H. Hondermarck,et al.  Neurotrophins and their receptors in breast cancer. , 2012, Cytokine & growth factor reviews.

[12]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[13]  A. Hill,et al.  Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase , 2011, Breast Cancer Research.

[14]  R. Tibshirani The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[15]  M. Bullock,et al.  FOXO factors and breast cancer: outfoxing endocrine resistance. , 2016, Endocrine-related cancer.

[16]  P. Cassoni,et al.  Oxytocin Receptor Signaling in Myoepithelial and Cancer Cells , 2005, Journal of Mammary Gland Biology and Neoplasia.

[17]  I. Azimi,et al.  Calcium influx pathways in breast cancer: opportunities for pharmacological intervention , 2014, British journal of pharmacology.

[18]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[19]  Niall O'Higgins,et al.  Caspase 3 in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  R. McPherson,et al.  The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[22]  Qiang Hu,et al.  Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium. , 2016, Carcinogenesis.

[23]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[24]  S. Dairkee,et al.  Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women , 2011, Carcinogenesis.

[25]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  O Sukocheva,et al.  Role of sphingolipids in oestrogen signalling in breast cancer cells: an update. , 2014, The Journal of endocrinology.

[27]  Wei Pan,et al.  Predictor Network in Penalized Regression with Application to Microarray Data” , 2009 .

[28]  Xiaodong Wang,et al.  DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis , 1997, Cell.

[29]  K. Claffey,et al.  Inhibition of breast cancer cell migration by activation of cAMP signaling , 2015, Breast Cancer Research and Treatment.

[30]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[31]  Cengizhan Ozturk,et al.  Pathway analysis of high-throughput biological data within a Bayesian network framework , 2011, Bioinform..

[32]  R. Vadlamudi,et al.  Role of Estrogen Receptor Signaling in Breast Cancer Metastasis , 2011, International journal of breast cancer.

[33]  S. Conzen,et al.  The role of adrenergic signaling in breast cancer biology. , 2013, Cancer biomarkers : section A of Disease markers.

[34]  Hasan H. Otu,et al.  Bayesian Pathway Analysis of Cancer Microarray Data , 2014, PloS one.

[35]  G. Baldassarre,et al.  Roles of CDKN1B in cancer? , 2015, Aging.

[36]  M. Young,et al.  Targeting AMPK for cancer prevention and treatment , 2015, Oncotarget.

[37]  Yong Lin,et al.  Tumor necrosis factor and cancer, buddies or foes? , 2008, Acta Pharmacologica Sinica.

[38]  Y. Tsujimoto,et al.  Role of Bcl‐2 family proteins in apoptosis: apoptosomes or mitochondria? , 1998, Genes to cells : devoted to molecular & cellular mechanisms.

[39]  E. Niemitz Ras pathway activation in breast cancer , 2013, Nature Genetics.

[40]  Stefan Wiemann,et al.  KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor , 2009, Bioinform..

[41]  Nir Friedman,et al.  Probabilistic Graphical Models - Principles and Techniques , 2009 .

[42]  Ichigaku Takigawa,et al.  Mining metabolic pathways through gene expression , 2010, Bioinform..

[43]  Kathleen Marchal,et al.  Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration , 2015, PloS one.

[44]  Joyce Lee,et al.  PI3K/Akt/mTOR inhibitors in breast cancer , 2015, Cancer biology & medicine.

[45]  Hongzhe Li,et al.  In Response to Comment on "Network-constrained regularization and variable selection for analysis of genomic data" , 2008, Bioinform..